Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
35 hedge funds and large institutions have $9.4M invested in Checkpoint Therapeutics in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.54% less ownership
Funds ownership: 1.77% → 1.23% (-0.54%)
5% less funds holding
Funds holding: 37 → 35 (-2)
31% less capital invested
Capital invested by funds: $13.6M → $9.4M (-$4.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$521K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$447K |
| 3 |
State Street
Boston,
Massachusetts
|
+$258K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$165K |
| 5 |
Millennium Management
New York
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.67M |
| 2 |
Squarepoint
New York
|
-$49K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$42K |
| 4 |
Bank of New York Mellon
New York
|
-$32.3K |
| 5 |
Renaissance Technologies
New York
|
-$12.9K |
CKPT Hedge Fund Activity: Q4 2019 in Review
35 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2019, worth a combined $9.4M — down 31% from $13.6M a quarter earlier.
Fund positioning in CKPT was balanced in Q4 2019: 5 funds opened new positions, 5 closed out, 14 added to existing stakes and 7 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $521K. The largest seller was BlackRock, cutting an estimated $1.67M.
- 35 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2019, down from 37 in Q3 2019.
- Funds reported $9.4M of Checkpoint Therapeutics stock for Q4 2019, down 31% quarter-over-quarter.
- 5 funds opened new Checkpoint Therapeutics positions in Q4 2019 and 5 closed out, a net change of 0 holders.
- The largest Checkpoint Therapeutics buyer in Q4 2019 was Anson Funds Management, an estimated $521K added.
- The largest Checkpoint Therapeutics seller in Q4 2019 was BlackRock, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2019.